The Optimal Anti-Coagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial
Discussion The OCEAN trial is a multicenter randomized controlled trial evaluating two antithrombotic treatment strategies for patients with risk factors for stroke after apparently successful AF ablation. We hypothesize that rivaroxaban will reduce the occurrence of clinically overt stroke, systemic embolism, and covert stroke when compared to ASA alone.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Arrhythmia | Atrial Fibrillation | Bleeding | Brain | Cardiology | Heart | Hemorrhagic Stroke | Ischemic Stroke | MRI Scan | Neurology | Stroke